A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their presentation, Redeye analyst Oscar Bergman moderated a Q&A session.
Visit from Beckman Coulter Diagnostics focused on market development
We had the pleasure of welcoming our long-term partner Beckman Coulter Diagnostics this week for valuable discussions on the continued sales and market development for our IRMA and ELISA portfolio. Their strong market presence and ability to effectively navigate a...
